Apyx Medical is plotting the commercial launch of a new body contouring system, after the US Food and Drug Administration (FDA) cleared the technology to support a range of aesthetic treatments.
The US company鈥檚 AYON system is an all-in-one platform for aesthetic surgical procedures. The device supports Apyx鈥檚 existing invasive procedure, branded as Renuvion, a therapy that combines helium plasma and radiofrequency (RF) energy to tighten loose skin.
The FDA clearance also includes ultrasound-assisted liposuction and electrocoagulation to support procedures requiring the removal of excess tissue, along with several others.
Apyx says AYON integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities. The company plans to launch the system to certain surgeons during the second half of 2025.
Body contouring, the umbrella term given to any procedure that reshapes an area of the body, has entered a new and uncertain era. Pressure from the booming glucagon-like peptide 1 receptor agonists (GLP-1RAs) market has meant that some procedures are fading in popularity. Equally, some body contouring market segments, which include those that remove saggy skin, have become popular as patients on weight loss drugs lose significant amounts of weight in a short time frame.
Apyx Medical鈥檚 CEO Charie Goodwin said: 鈥淭he aesthetics market is expecting a rapid increase in body contouring procedures over the course of the next year, as the more than 15 million patients currently using GLP-1RA drugs achieve rapid weight loss and seek solutions for addressing their loose and lax skin and reshaping their new bodies. AYON provides surgeons with all the necessary solutions in one device for meeting the needs of these patients.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFigures from the British Association of Aesthetic Plastic Surgeons (BAAPS) showed a 5% rise in cosmetic surgical procedures in 2024. A total of 27,462 procedures were conducted in the UK, with the most popular surgery performed being breast augmentation.
吃瓜黑料网 by GlobalData forecasts the aesthetic body contouring device market to reach $978m by 2034, up from $721m in 2024. Minimally invasive devices will contribute around 40% of the market by 2034, whilst non-invasive devices will account for the other 60%. The North American market is dominated by Allergan Aesthetics.
Allergan Aesthetics was acquired by pharma giant AbbVie for $63bn in 2020 and has a range of marketed devices for body contouring. The company also markets Botox (onabotulinumtoxinA), which generates annual sales of approximately $1.7bn in the US alone.
